← Leaderboards
Nagi B Kumar
H. Lee Moffitt Cancer Ctr & Res Inst
$8,902,562
Attributed
$8,902,562
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2007–24$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,902,562 · 4
By mechanism
R01$7,016,341 · 2
P20$1,886,221 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMorbidity - Disease RateEvaluationBaseMonitorDisease ProgressionPreventLower Urinary Tract SymptomsPlacebosPathway InteractionsMolecularIncidenceIndexingDoseBiologicalMalignant Neoplasm Of ProstateProstate-Specific AntigenApoptosisIn VitroBiopsyChemopreventionRandomizedClinical TrialsReporting
Grant awards (25)
Phase II Clinical trial of GTC in Men on Active Surveillance$574,580
R01 · FY2024 · CA · contact PI
Phase II Clinical trial of GTC in Men on Active Surveillance$592,725
R01 · FY2023 · CA · contact PI
Phase II Clinical trial of GTC in Men on Active Surveillance$10,124
R01 · FY2022 · CA · contact PI
Phase II Clinical trial of GTC in Men on Active Surveillance$615,210
R01 · FY2021 · CA · contact PI
Phase II Clinical trial of GTC in Men on Active Surveillance$615,210
R01 · FY2020 · CA · contact PI
Phase II Clinical trial of GTC in Men on Active Surveillance$604,823
R01 · FY2019 · CA · contact PI
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet$108,373
P20 · FY2013 · MD · contact PI
Training/Education Core$59,876
P20 · FY2013 · MD · contact PI
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet$320,681
P20 · FY2012 · MD · contact PI
Training/Education Core$131,734
P20 · FY2012 · MD · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$688,824
R01 · FY2011 · CA · contact PI
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet$312,250
P20 · FY2011 · MD · contact PI
Training/Education Core$122,378
P20 · FY2011 · MD · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$96,936
R01 · FY2011 · CA · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$715,845
R01 · FY2010 · CA · contact PI
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet$301,931
P20 · FY2010 · MD · contact PI
Training/Education Core$120,245
P20 · FY2010 · MD · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$86,468
R01 · FY2010 · CA · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$707,275
R01 · FY2009 · CA · contact PI
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet$266,654
P20 · FY2009 · MD · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$147,616
R01 · FY2009 · CA · contact PI
Training/Education Core$142,099
P20 · FY2009 · MD · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$689,729
R01 · FY2008 · CA · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$127,959
R01 · FY2008 · CA · contact PI
Phase II Clinical Trial of Polyphenon E in Prostate Cancer$743,017
R01 · FY2007 · CA · contact PI